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6 February 2014 
EMA/74168/2014 
Human Medicines Development and Evaluation  
Benefit-risk methodology project 
Update on work package 5: Effects Table pilot (Phase I) 
1.  Background 
The aim of the European Medicines Agency (EMA) Benefit-Risk Methodology Project is to enhance the 
transparency of the benefit-risk decision-making process, and facilitate the communication of the 
rationale for each decision, both within the regulatory system and to the public. The project consists of 
five consecutive work packages1. The first four work packages formed the research phase of the 
project, and the fifth work package, currently ongoing, is intended as initial implementation and 
training. One of the recommendations of Work package 4 report2 is the use of the Effects Table (ET) as 
a tool to summarise the key benefits and risks, and supplement the benefit-risk section of the CHMP3 
assessment report by presenting a compact and consistent display of the salient data and uncertainties 
that are drivers of the decision (Annex 1).  
2.  First pilot 
After an initial period of testing, the CHMP agreed in November 2012 to initiate a five-month pilot of 
the ET (Annex 1). The pilot was agreed to last from January to May 2013 involving ongoing procedures 
for initial market authorisation. The rapporteur of each product was responsible for preparing the ET, 
and the project team provided support and guidance as necessary. In total, nine products were 
included in the pilot, four at Day 120 and five at Day 180 of the assessment process. All the tables 
were completed by the rapporteur/assessors on time with minimum support from the project team. 
Each ET was circulated by the rapporteur to the CHMP as a separate document complementing either 
the Day 120 or the Day 180 Assessment Report. A short feedback questionnaire was sent to the 
participating rapporteurs. The feedback collected presented, on average, a positive view on the use of 
the table as an aid in communicating the benefit-risk balance. It was noted that the table is a useful 
display of the key issues that can improve the transparency of the benefit-risk assessment, and 
support the communication with the other committees and the public. It was also noted that the ET 
should form an integral part of the benefit-risk section and be compiled early in the assessment 
process. Consideration should be given on improving the presentation of data from multiple trials and 
                                               
1 European Medicines Agency, Benefit-Risk Methodology Project. 2009, 
http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/07/WC500109477.pdf. 
2 European Medicines Agency, Work Package 4 Report: Benefit-risk tools and processes 2012, 
http://www.ema.europa.eu/docs/en_GB/document_library/Report/2012/03/WC500123819.pdf. 
3 EMA’s Committee for Medicinal Products for Human Use 
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on the support that might be required from EMA for the finalisation of an ET. Following completion of 
this initial phase, the CHMP agreed to initiate a wider pilot of the ET (Annex 1), taking into 
consideration the feedback received. 
Currently, there is no requirement to include an ET or any other framework or methodology into a 
Market Authorisation Application (MAA). The project’s Steering Group has noted a number of cases of 
benefit-risk methods submitted by companies, either in the context of a Scientific Advice procedure or 
initial MAA. If this is considered useful, applicant companies are encouraged to include any framework 
or methodology in their applications, in addition to the conventional documentation, in order to gain 
more experience with such approaches. Additionally, questions on such methodologies can be 
addressed in the context of a Scientific Advice procedure. 
3.  Next steps 
The CHMP agreed to initiate a phase II pilot of the ET. The main points are outlined below. 
• Update the template/guidance of the ET based on the feedback received. 
• Integrate the ET within the benefit-risk section of the assessment report. 
• Pilot the ET on initial applications of new active substances starting from September to 
December 2013. The aim is to include at least ten products in this phase. 
• Both Rapporteur and Co-rapporteur will prepare an ET that will be included in the Day 80 
assessment reports. The tables will be updated throughout the procedure until the Day 210. 
• Training and support will be provided by the project team and the Steering Group. 
• The CHMP will have an interim evaluation of this pilot phase at mid-2014. 
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Annex 1 - Hypothetical example of an Effects Table 
Table 1. Effects Table for vandetanib / Based on the EPAR EMEA/H/C/002315 published on 02/03/2012 
 Effect Short 
Description 
Unit Plac
ebo 
Vandet
anib 
Uncertainties/ 
Strength of evidence 
References 
Fa
vo
u
ra
b
le
 
PFS (HR) From 
randomization to 
progression or 
death (blinded 
independent 
review) 
N/A 1 0.46 
95% CI: 
(0.31, 
0.69) 
Large effect in overall 
population. Consistent 
and significant effect on 
PFS but not OS (too 
early?) 
 
Only a very low number 
of patients with definite 
RET mutation negative 
status at baseline. Lower 
efficacy? 
 
No clear effect on 
PRO/QoL (missing data) 
See Discussion on 
Clinical Efficacy.  
 
 
 
 
Single-arm study in 
RET negative patients 
post-approval. 
 
 
 
See Discussion on 
Clinical Efficacy. 
PFS 
(median) 
Weibull model Mo 19.3 30.5 
ORR Proportion of 
complete or 
partial responders 
(>=30% decrease 
unidimensional) 
RECIST 
% 13 45 
U
n
fa
vo
u
ra
b
le
 
Diarrhoea  
Grade 3-4 
Increase of ≥7 
stools per day 
over baseline; 
incontinence; Life-
threatening 
% 2.0 10.8 Duration of follow up in 
the pivotal study is short 
vs. the need for long 
duration of treatment. 
 
Risk of developing 
further major cardiac 
SAEs including Torsades 
de pointe? 
Risk of dehydration and 
renal/cardiac risks (see 
SmPC 4.4) 
 
Restrict to symptomatic 
and aggressive disease 
(see SmPC 4.1).  
 
Explore lower dose (see 
See Table 20. Summary 
of the RMP) 
QTc related 
events  
Grade 3-4 
QTc >0.50 
second; life 
threatening; 
Torsade de pointes 
% 1.0 13.4 
Infections 
Grade 3-4 
IV antibiotic, 
antifungal, or 
antiviral 
intervention 
indicated; Life-
threatening 
% 36.4 49.8 
Abbreviations: PFS, progression-free survival; ORR objective response rate; Mo, months; OS, overall 
survival; RET, “rearranged during transfection” gene, see text. 
